ANAVEX LIFE SCIENCES CORP. (AVXL) completed the clinical conduct of two blarcamesine (ANAVEX®2-73) pharmacology studies in healthy volunteers: an absorption, distribution, metabolism and excretion (ADME) study and a drug-drug interaction (DDI) study. The company says the studies address clinical pharmacology data recommended by the FDA and expects the data to support its FDA-focused development program.
The company also reported FDA clearance of its investigational new drug application for Fragile X syndrome. It has an upcoming meeting with the FDA in November to discuss adding pediatric participants to the Phase 3 Rett syndrome study. Blarcamesine is being developed for early Alzheimer’s disease, Rett syndrome and Fragile X syndrome.
Anavex Life Sciences Corp. (AVXL) said the FDA notified it that it may proceed with its planned clinical study of blarcamesine for Fragile X syndrome. The investigational new drug application is now open for clinical investigation in the United States.
The planned Phase 2a study is randomized, double-blind, placebo-controlled and dose-ranging. It will evaluate the safety, tolerability and pharmacokinetics of oral blarcamesine in approximately 60 adult males, with behavioral and cognitive measures as secondary endpoints. A peer-reviewed mouse-model study reported dose-related improvement in EEG abnormalities after 14 days of oral blarcamesine. The drug remains investigational; its safety and efficacy in Fragile X syndrome have not been established.
Anavex Life Sciences Corp. (AVXL) is the issuer named in a Form 3 identifying Adrian Senderowicz as a director.
ANAVEX LIFE SCIENCES CORP. reported that Sandra Boenisch, PFO & Treasurer, had four previously granted stock-option awards become immediately vested and exercisable on September 24, 2026. The options cover 20,000 shares at a $10.09 exercise price, 25,000 at $8.57, 25,000 at $5.36 and 25,000 at $8.58. The vesting followed the board election at the 2026 Annual Meeting, which the company described as a “change in control” under its incentive plans and her employment agreement.
ANAVEX LIFE SCIENCES CORP. (AVXL) reported that its September 24, 2026 director election triggered a “change in control” under its 2015, 2019 and 2022 Omnibus Incentive Plans and the employment agreement of Principal Financial Officer Sandra Boenisch. Because the election was contested, only Jiong Ma, Ph.D., Peter Donhauser, D.O., and Claus van der Velden, Ph.D. qualified as “Incumbent Directors” afterward, leaving them below a board majority. As a result, all outstanding and unvested awards under the plans, including awards held by Ms. Boenisch, immediately became fully vested and exercisable under the applicable plan and award-agreement terms. Stockholders elected company nominees Jiong Ma, Peter Donhauser, Axel Paeger, Gautam Patel, Adrian Senderowicz and Claus van der Velden; none of the six nominees proposed by PVG Asset Management Corporation was elected. Grant Thornton LLP was ratified as the independent registered accounting firm for the fiscal year ending September 30, 2026.
ANAVEX LIFE SCIENCES CORP. (AVXL) is the subject of a proxy solicitation by PVG Asset Management Corporation and associated participants, who have filed a definitive proxy statement on Schedule 14A and are using a GOLD Universal Proxy Card for the Company’s 2026 annual meeting of stockholders.
On September 16, 2026, PVG held an online investor presentation and question-and-answer session via webcast at 10:00 a.m. Eastern Time; the presentation materials are attached as Exhibit 1 and a written transcript as Exhibit 2. The filing identifies PVG and six individuals as participants and includes standard cautionary language regarding forward-looking statements, urging stockholders to carefully review PVG’s definitive proxy statement and related materials available on the SEC’s website before voting.
ANAVEX LIFE SCIENCES CORP. (AVXL) is the subject of a proxy solicitation by PVG Asset Management Corporation and associated participants, who have filed a definitive proxy statement and a GOLD Universal Proxy Card seeking to elect six nominees to the Board at the 2026 annual meeting of stockholders.
PVG, which reports owning 337,663 shares of Anavex, outlines a planned “first 100 days” agenda if its nominees join the Board. The plan includes recruiting a new CEO with central nervous system and rare disease experience, rebuilding the clinical team, creating a Board-level clinical committee for trial oversight, and engaging outside experts on trial design and risk. PVG also describes potential capital-raising approaches, possible strategic partnerships with larger pharmaceutical companies, reviews of pipeline assets and patents, and governance steps such as addressing ongoing litigation related to the former CEO’s termination, enhancing Board oversight, and increasing investor and public relations efforts. PVG encourages stockholders to review its definitive proxy materials and consider using the GOLD Universal Proxy Card in connection with the 2026 annual meeting.